Vendor, Waltham, MA
Bostongene Corporation
UEI PP3RJC2N6528, CAGE 7LKK4
1 award and $302,039 obligated between September 10, 2024 and September 10, 2024, 0% under full and open competition, against 1.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
How it wins
Awards by competition, set-aside and type.
| Not Competed | 1 |
| Purchase Order | 1 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Deep Sequencing Analysis Services to Monitor Copanlisib/Rituximab Combination Treatment
National Institutes of Health, NIH NCI
Special noticeNAICS 541380Waltham, MA75N91024NOI6831928Awarded to Bostongene Corporation
Posted Feb 12, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91024P00398Purchase Order, September 10, 2024, Not Competed, 1 offersSolicitation | NIH NCINational Institutes of Health | Deep Sequencing Analysis Services to Monitor Copanlisib/Rituximab Combination TreatmentNAICS 541380, PSC Q301 | $302,039 |
- Places of performance
- Massachusetts
- Product and service codes
- Q301 Reference Laboratory Testing
- Transactions
- 1 across 1 awards